Erik T. Goluboff
AuthID: R-00K-8HY
1
TITLE: A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) plus tremelimumab (T) plus enfortumab vedotin (EV) or D plus EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
AUTHORS: Powles, Thomas; Drakaki, Alexandra; Teoh, Jeremy Yuen Chun; Grande, Enrique; Fontes Sousa, Mario; Porta, Camillo; Wu, Esther; Goluboff, Erik T.; Ho, Svetlana; Hois, Stephan; Gupta, Ashok Kumar; Catto, James W. F.;
PUBLISHED: 2022, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, ISSUE: 6
AUTHORS: Powles, Thomas; Drakaki, Alexandra; Teoh, Jeremy Yuen Chun; Grande, Enrique; Fontes Sousa, Mario; Porta, Camillo; Wu, Esther; Goluboff, Erik T.; Ho, Svetlana; Hois, Stephan; Gupta, Ashok Kumar; Catto, James W. F.;
PUBLISHED: 2022, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, ISSUE: 6
INDEXED IN: 
WOS
WOS